KalVista Pharmaceuticals, Inc. (FRA:4XC1)

KalVista Pharmaceuticals Statistics

Total Valuation

FRA:4XC1 has a market cap or net worth of EUR 630.76 million. The enterprise value is 607.84 million.

Market Cap	630.76M
Enterprise Value	607.84M

Important Dates

The next estimated earnings date is Friday, December 5, 2025.

Earnings Date	Dec 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	50.55M
Shares Outstanding	n/a
Shares Change (YoY)	+29.51%
Shares Change (QoQ)	+0.72%
Owned by Insiders (%)	2.17%
Owned by Institutions (%)	80.93%
Float	30.40M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	505.98
PB Ratio	17.69
P/TBV Ratio	17.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.42
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.14

Financial Position

The company has a current ratio of 5.37, with a Debt / Equity ratio of 3.39.

Current Ratio	5.37
Quick Ratio	5.16
Debt / Equity	3.39
Debt / EBITDA	n/a
Debt / FCF	-0.82
Interest Coverage	-21.79

Financial Efficiency

Return on equity (ROE) is -190.18% and return on invested capital (ROIC) is -70.75%.

Return on Equity (ROE)	-190.18%
Return on Assets (ROA)	-60.98%
Return on Invested Capital (ROIC)	-70.75%
Return on Capital Employed (ROCE)	-114.49%
Revenue Per Employee	4,617
Profits Per Employee	-657,583
Employee Count	270
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:4XC1 has paid 4.85 million in taxes.

Income Tax	4.85M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.73% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+29.73%
50-Day Moving Average	10.15
200-Day Moving Average	10.81
Relative Strength Index (RSI)	62.21
Average Volume (20 Days)	57

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.75

Income Statement

In the last 12 months, FRA:4XC1 had revenue of EUR 1.25 million and -177.55 million in losses. Loss per share was -3.45.

Revenue	1.25M
Gross Profit	-51.95M
Operating Income	-177.28M
Pretax Income	-172.70M
Net Income	-177.55M
EBITDA	-176.43M
EBIT	-177.28M
Loss Per Share	-3.45

Balance Sheet

The company has 167.38 million in cash and 121.04 million in debt, giving a net cash position of 46.34 million.

Cash & Cash Equivalents	167.38M
Total Debt	121.04M
Net Cash	46.34M
Net Cash Per Share	n/a
Equity (Book Value)	35.66M
Book Value Per Share	0.71
Working Capital	146.45M

Cash Flow

In the last 12 months, operating cash flow was -146.16 million and capital expenditures -614,563, giving a free cash flow of -146.77 million.

Operating Cash Flow	-146.16M
Capital Expenditures	-614,563
Free Cash Flow	-146.77M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-14,220.83%
Pretax Margin	-13,853.30%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:4XC1 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.51%
Shareholder Yield	-29.51%
Earnings Yield	-28.15%
FCF Yield	-23.27%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:4XC1 has an Altman Z-Score of -4.92 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.92
Piotroski F-Score	1